search
Back to results

Neuropathic Pain in Pregnancy

Primary Purpose

Pain, Pregnancy

Status
Completed
Phase
Not Applicable
Locations
United States
Study Type
Interventional
Intervention
painDETECT Questionnaire
Pain Catastrophizing Scale
Pain Intensity Scale, Pain Interference Scale, Pain Behavior Scale
Beck Depression Inventory
Visual Analogue Scale
Patient's Global Impression of Change Scale & Clinical Global Impression-Global Improvement Scale
Transcranial Magnetic Stimulation
Sponsored by
University of Arkansas
About
Eligibility
Locations
Arms
Outcomes
Full info

About this trial

This is an interventional supportive care trial for Pain focused on measuring neuropathic pain, pregnancy

Eligibility Criteria

18 Years - 45 Years (Adult)FemaleDoes not accept healthy volunteers

Part A

Inclusion Criteria:

  • age 18-45 years old,
  • ability to give informed consent,
  • viable pregnancy, and
  • enrollment prior or equal to 24 weeks gestation

Exclusion Criteria:

  • Active or history of substance use disorder within the past year
  • Non-English speaking

Part B

Inclusion Criteria:

  • Subjects enrolled in Part A and willing to consent to Part B of this protocol
  • Pregnant with current chronic neuropathic pain
  • Subjects failed treatment with amitriptyline or nortriptyline as defined by one of the following:

    • no clinical improvement following a 4-week trial of amitriptyline or nortriptyline (i.e., CGI-I score ≥4)
    • an inability to tolerate the medication (i.e., side effects)
  • Subjects must pass the TMS Safety Checklist Adult Safety Screen (TASS).
  • Subjects should be off medication, which can lower seizure thresholds (e.g., amitriptyline and nortriptyline) for at least two weeks prior to study entry.
  • Subjects with neuropathic pain including those with diagnosis of spinal cord injury, fibromyalgia, compression neuropathies (including diabetic peripheral neuropathy), post stroke pain, and multiple sclerosis
  • Subjects with a baseline VAS score greater than 30

Exclusion Criteria:

  • Current or past history of a seizure disorder (e.g., epilepsy)
  • Current history of preeclampsia
  • Current or history of brain lesions (e.g., aneurysm)
  • History of major head trauma (e.g., stroke; previous cranial neurosurgery)
  • Ferromagnetic metal in the head, neck, or chest (e.g., plates or pins, bullets, shrapnel)
  • Microprocessor implants in the head (e.g., cochlear implants) or life-sustaining microprocessor implants anywhere in the body (e.g., prosthetic cardiac valves)
  • Cardiac pacemaker
  • Active or inactive implants (e.g., deep brain stimulators, vagus nerve stimulators)
  • Active treatment with medications that lower seizure threshold (e.g., bupropion, amitriptyline, nortriptyline, or other TCA)
  • Increased intracranial pressure (which lowers seizure threshold)
  • Implanted medication pumps
  • Intracardiac lines
  • Significant heart disease defined as heart disease that causes moderate to severe symptoms and/or is characterized by moderate to severe pathology, including a recent history of myocardial infarction and heart failure with an ejection fraction of less than 30% or with a New York Heart Association Functional Classification of Class III or IV.
  • Bipolar disorder (to reduce the risk of mania)
  • History of suicide attempt(s)
  • Family history of epilepsy
  • Heavy alcohol consumption within the past 48 hours
  • Permanent makeup or tattoos with metallic dyes

Sites / Locations

  • University of Arkansas For Medical Sciences

Arms of the Study

Arm 1

Arm 2

Arm 3

Arm 4

Arm Type

Other

Other

Other

Experimental

Arm Label

Part A - Neuropathic Pain

Part A - Non-Neuropathic Pain

Part A - Control

Part B - rTMS

Arm Description

Subjects with a score of ≥ 13 on the painDETECT Questionnaire (PDQ) will be assigned to the Neuropathic Pain group.

Subjects with a score of ≥ 1 or ≤ 12 on the painDETECT Questionnaire (PDQ) will be assigned to the Non-Neuropathic Pain group.

Subjects with a score of score = 0 on the painDETECT Questionnaire (PDQ) will be assigned to the Control group.

Subjects from the Neuropathic Pain group will be invited to participate in the Part B rTMS group to receive repetitive transcranial magnetic stimulation (rTMS).

Outcomes

Primary Outcome Measures

Change From Baseline Visual Analogue Scale for Pain
100 mm line scale that is subject administered to subjectively rate current pain symptoms. The subject will be instructed to draw a single vertical line that best describes current state. The total score ranges from 0-100 with higher numbers indicating worse outcomes. The VAS will be administered at every subject visit.

Secondary Outcome Measures

Full Information

First Posted
November 13, 2015
Last Updated
June 2, 2021
Sponsor
University of Arkansas
search

1. Study Identification

Unique Protocol Identification Number
NCT02608463
Brief Title
Neuropathic Pain in Pregnancy
Official Title
Neuropathic Pain in Pregnancy
Study Type
Interventional

2. Study Status

Record Verification Date
May 2021
Overall Recruitment Status
Completed
Study Start Date
January 1, 2016 (Actual)
Primary Completion Date
April 19, 2019 (Actual)
Study Completion Date
April 19, 2019 (Actual)

3. Sponsor/Collaborators

Responsible Party, by Official Title
Sponsor
Name of the Sponsor
University of Arkansas

4. Oversight

Studies a U.S. FDA-regulated Drug Product
No
Studies a U.S. FDA-regulated Device Product
Yes
Data Monitoring Committee
Yes

5. Study Description

Brief Summary
This will be the first study to investigate the use of rTMS in the treatment of neuropathic pain in pregnancy. This study will enroll 60 pregnant subjects, age 18-45. All participants will receive treatment as usual. Subjects diagnosed with neuropathic pain will be offered rTMS as a treatment option.
Detailed Description
Neuropathic pain is a common pain disorder that is caused by problems in the nervous system. It affects more women than men and commonly occurs in pregnancy. Physicians have little information to guide their treatment of neuropathic pain in pregnancy. The overall goal of this study is to define the course, management, and pregnancy outcomes of neuropathic pain in pregnancy and the acute postpartum period. It is difficult to manage neuropathic pain in pregnancy as treatment options must minimize their risk to the unborn child as they have a direct effect on infant outcomes through their exposure in utero. Thus, other treatments are needed. Repetitive transcranial magnetic stimulation (rTMS) may be an acceptable alternative to medications. Transcranial magnetic stimulation uses a magnetic force to change the way nerves work in the brain. This non-invasive and localized mechanism of action makes it attractive for use in special populations, such as pregnancy. Study visits will occur approximately every 4-6 weeks during pregnancy until approximately 3 months postpartum for a maximum of 12 visits.

6. Conditions and Keywords

Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Pain, Pregnancy
Keywords
neuropathic pain, pregnancy

7. Study Design

Primary Purpose
Supportive Care
Study Phase
Not Applicable
Interventional Study Model
Parallel Assignment
Model Description
All subjects will participate in Part A, receive standard of care and complete the painDETECT Questionnaire (PDQ) to be assigned to 1 of 3 groups based on the PDQ score. Subjects in Part A will complete the following at study entry and each study visit: the Beck Depression Inventory (BDI), Visual Analogue Scale (VAS), Pain Catastrophizing Scale (PCS), and measures of pain intensity, interference, behavior. At each visit after study entry, subjects will complete the Patients' Global Impression of Change scale (PGIC); clinicians will complete the Clinical Global Impression-Global Improvement scale (CGI-I). Subjects in Part B will receive rTMS and be followed daily until day 29 after last rTMS session. For each session, subjects will complete a VAS prior, immediately after, and 60 minutes post, day 22 & day 29; a BDI on Days 1, 5, 12, 22, & 29; on days 5, 12, 22, & 29 subjects will complete the PGIC; clinicians will complete the CGI-I.
Masking
None (Open Label)
Allocation
Non-Randomized
Enrollment
15 (Actual)

8. Arms, Groups, and Interventions

Arm Title
Part A - Neuropathic Pain
Arm Type
Other
Arm Description
Subjects with a score of ≥ 13 on the painDETECT Questionnaire (PDQ) will be assigned to the Neuropathic Pain group.
Arm Title
Part A - Non-Neuropathic Pain
Arm Type
Other
Arm Description
Subjects with a score of ≥ 1 or ≤ 12 on the painDETECT Questionnaire (PDQ) will be assigned to the Non-Neuropathic Pain group.
Arm Title
Part A - Control
Arm Type
Other
Arm Description
Subjects with a score of score = 0 on the painDETECT Questionnaire (PDQ) will be assigned to the Control group.
Arm Title
Part B - rTMS
Arm Type
Experimental
Arm Description
Subjects from the Neuropathic Pain group will be invited to participate in the Part B rTMS group to receive repetitive transcranial magnetic stimulation (rTMS).
Intervention Type
Behavioral
Intervention Name(s)
painDETECT Questionnaire
Other Intervention Name(s)
PDQ
Intervention Description
This self-report questionnaire consists of 7 questions that address the quality of neuropathic pain syndromes. The first 5 questions ask about the gradation of pain, question 6 asks about the pain course pattern and question 7 asks about radiating pain. There are 4 additional questions (not counted in the total score) which asks the subject to rate their pain now and over the last 4 weeks and to mark on a body chart if there is pain radiating into other parts of the body.
Intervention Type
Behavioral
Intervention Name(s)
Pain Catastrophizing Scale
Other Intervention Name(s)
PCS
Intervention Description
The PCS is a 13-item self-report scale. It asks subjects to reflect on past painful experiences, and to indicate the degree to which they experienced each of 13 thoughts or feelings when experiencing pain, on 5-point scales with the end points (0) not at all and (4) all the time. The PCS yields a total score and three subscale scores assessing rumination, magnification, and helplessness.
Intervention Type
Behavioral
Intervention Name(s)
Pain Intensity Scale, Pain Interference Scale, Pain Behavior Scale
Other Intervention Name(s)
Pain Measures
Intervention Description
The 3-item, self-report Pain Intensity assesses how much a person hurts. The first 2 items assess pain intensity over the past 7 days; the last item asks subject to rate pain intensity "right now." The 4-item, self-report Pain Interference measures the consequences of pain on relevant aspects of subject's life. It includes impairment in subject's social, cognitive, emotional, physical, & recreational activities. It also incorporates items about sleep and enjoyment of life. It assesses pain interference over the past 7 days. The 7-item, self-report Pain Behavior measures behaviors that typically indicate to others that an individual is experiencing pain. Measures include observations (sighing, crying), behaviors (resting, guarding, facial expressions, asking for help), & verbal reports of pain. It assesses pain interference over the past 7 days. All three scales, derived from the Patient Reported Outcomes Measurement Information System (PROMIS), are not disease specific.
Intervention Type
Behavioral
Intervention Name(s)
Beck Depression Inventory
Other Intervention Name(s)
BDI
Intervention Description
The BDI is a widely used instrument that has been used in both clinical and non-clinical setting measuring depressive symptoms. It is a 21 item questionnaire with 4-5 responses for each question. Responses are coded 0-3 for the 4 point scales. The 5 point scales include an additional 2a and 2b response code. The symptom categories reflect overt behavioral manifestations of depression. The instrument has both a high degree of reliability and validity (Beck, Ward, Mendelson, Mock & Erbaugh, 1961).
Intervention Type
Behavioral
Intervention Name(s)
Visual Analogue Scale
Other Intervention Name(s)
VAS
Intervention Description
100 mm line scale that is subject administered to subjectively rate current pain symptoms. The subject will be instructed to draw a single vertical line that best describes current state.
Intervention Type
Behavioral
Intervention Name(s)
Patient's Global Impression of Change Scale & Clinical Global Impression-Global Improvement Scale
Other Intervention Name(s)
PGIC & CGI-I
Intervention Description
The PGIC gives a global rating of change in symptoms, activities, emotion, and overall quality of life related to the subject's pain condition. This is a self-rated scale. The CGI-I gives a global rating of the improvement/change in the symptoms since the last study visit. This is administered by the MD.
Intervention Type
Device
Intervention Name(s)
Transcranial Magnetic Stimulation
Other Intervention Name(s)
NeuroStar® TMS
Intervention Description
Subjects will undergo daily repetitive transcranial magnetic stimulation (rTMS), defined as Monday through Friday, for a total of 10 consecutive sessions. rTMS will be applied using the NeuroStar TMS Therapy System through a figure-8 coil connected to a magnetic stimulator, which provides a biphasic pulse. The coil is applied to the primary motor cortex, M1, contralateral to the painful side. The optimal stimulus site, motor hot spot, will be determined according to visual detection of muscle twitches, and a resting motor threshold is defined as the minimal intensity necessary to induce at least one visible muscle twitch. An rTMS session consists of 10 trains at 90% intensity of resting motor threshold (one train, 100 pulses at 10 Hz; intertrain interval, 50s).
Primary Outcome Measure Information:
Title
Change From Baseline Visual Analogue Scale for Pain
Description
100 mm line scale that is subject administered to subjectively rate current pain symptoms. The subject will be instructed to draw a single vertical line that best describes current state. The total score ranges from 0-100 with higher numbers indicating worse outcomes. The VAS will be administered at every subject visit.
Time Frame
Baseline and end of study participation, an average of 194 days

10. Eligibility

Sex
Female
Minimum Age & Unit of Time
18 Years
Maximum Age & Unit of Time
45 Years
Accepts Healthy Volunteers
No
Eligibility Criteria
Part A Inclusion Criteria: age 18-45 years old, ability to give informed consent, viable pregnancy, and enrollment prior or equal to 24 weeks gestation Exclusion Criteria: Active or history of substance use disorder within the past year Non-English speaking Part B Inclusion Criteria: Subjects enrolled in Part A and willing to consent to Part B of this protocol Pregnant with current chronic neuropathic pain Subjects failed treatment with amitriptyline or nortriptyline as defined by one of the following: no clinical improvement following a 4-week trial of amitriptyline or nortriptyline (i.e., CGI-I score ≥4) an inability to tolerate the medication (i.e., side effects) Subjects must pass the TMS Safety Checklist Adult Safety Screen (TASS). Subjects should be off medication, which can lower seizure thresholds (e.g., amitriptyline and nortriptyline) for at least two weeks prior to study entry. Subjects with neuropathic pain including those with diagnosis of spinal cord injury, fibromyalgia, compression neuropathies (including diabetic peripheral neuropathy), post stroke pain, and multiple sclerosis Subjects with a baseline VAS score greater than 30 Exclusion Criteria: Current or past history of a seizure disorder (e.g., epilepsy) Current history of preeclampsia Current or history of brain lesions (e.g., aneurysm) History of major head trauma (e.g., stroke; previous cranial neurosurgery) Ferromagnetic metal in the head, neck, or chest (e.g., plates or pins, bullets, shrapnel) Microprocessor implants in the head (e.g., cochlear implants) or life-sustaining microprocessor implants anywhere in the body (e.g., prosthetic cardiac valves) Cardiac pacemaker Active or inactive implants (e.g., deep brain stimulators, vagus nerve stimulators) Active treatment with medications that lower seizure threshold (e.g., bupropion, amitriptyline, nortriptyline, or other TCA) Increased intracranial pressure (which lowers seizure threshold) Implanted medication pumps Intracardiac lines Significant heart disease defined as heart disease that causes moderate to severe symptoms and/or is characterized by moderate to severe pathology, including a recent history of myocardial infarction and heart failure with an ejection fraction of less than 30% or with a New York Heart Association Functional Classification of Class III or IV. Bipolar disorder (to reduce the risk of mania) History of suicide attempt(s) Family history of epilepsy Heavy alcohol consumption within the past 48 hours Permanent makeup or tattoos with metallic dyes
Overall Study Officials:
First Name & Middle Initial & Last Name & Degree
Shona L Ray-Grififth, MD
Organizational Affiliation
University of Arkansas
Official's Role
Principal Investigator
Facility Information:
Facility Name
University of Arkansas For Medical Sciences
City
Little Rock
State/Province
Arkansas
ZIP/Postal Code
72205
Country
United States

12. IPD Sharing Statement

Plan to Share IPD
No

Learn more about this trial

Neuropathic Pain in Pregnancy

We'll reach out to this number within 24 hrs